Ampalex-CX516-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAmpalexCat. No.: HY-10933CAS No.: 154235-83-3Synonyms: CX516; BDP 12; Ampakine CX516分式: CHNO分量: 241.29作靶點(diǎn): iGluR作通路: Membrane Transporter/Ion Channel; Neuronal Signaling儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-

2、20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 41 mg/mL (169.92 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 4.1444 mL 20.7220 mL 41.4439 mL5 mM 0.8289 mL 4.1444 mL 8.2888 mL10 mM 0.4144 mL 2.0722 mL 4.1444 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式

3、選擇適當(dāng)?shù)娜芙獍福渲魄罢?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.75 mg/mL (11.40 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.75 mg/mL (11.40 mM); C

4、lear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.75 mg/mL (11.40 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Ampalex (Ampakine CX516; CX516; BDP 12)AMPA受體陽性變構(gòu)調(diào)節(jié)劑，可作于阿爾茨海默病，精神分裂等。REFERENCES1. Broberg BV, Glenth?j BY, Dias R, et al. Reversal

5、of cognitive deficits by an ampakine (CX516) and sertindole in two animal models ofschizophrenia-sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 20092. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AM

6、PA receptors in a hippocampal slicemodel of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61.3. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology. 2008 Feb;33(3):465-72.4. ONeill MJ,

7、Witkin JM. AMPA receptor potentiators: application for depression and Parkinsons disease. Curr Drug Targets. 2007May;8(5):603-20.5. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderlyparticipants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.McePdfHeightCaution: Product has not been fully validated for medical applications.For resear